This article by Drug Development & Delivery highlights the importance of Contract Development and Manufacturing Organizations (CDMOs) for the pharma and biotech companies when it comes to advancing innovative therapies.
In this annual report, leading CDMOs speak with Drug Development & Delivery about how they are adapting to bio/pharma client needs. In addition, this report also discusses the integrated CDMO/CRO services offered by Quotient Sciences and how the company’s Translational Pharmaceutics® platform integrates formulation development, on-demand and adaptive GMP manufacturing, healthy volunteer clinical testing, data analysis and full regulatory support within a single organization.
To read more, check out the full article here on the Drug Development & Delivery website.